TY - JOUR
T1 - High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases
AU - Halfon, S.
AU - Paul, M.
AU - Steinberg, D.
AU - Nagler, A.
AU - Arenshtam, A.
AU - Kijel, D.
AU - Polacheck, I.
AU - Srebnik, M.
PY - 2009/7
Y1 - 2009/7
N2 - A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction 7Li(p,n)7Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.
AB - A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction 7Li(p,n)7Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.
KW - Accelerator-based BNCT
KW - Infectious diseases
KW - Liquid lithium
KW - Target
UR - http://www.scopus.com/inward/record.url?scp=67649451966&partnerID=8YFLogxK
U2 - 10.1016/j.apradiso.2009.03.075
DO - 10.1016/j.apradiso.2009.03.075
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19406650
AN - SCOPUS:67649451966
SN - 0969-8043
VL - 67
SP - S278-S281
JO - Applied Radiation and Isotopes
JF - Applied Radiation and Isotopes
IS - 7-8 SUPPL.
ER -
